Physician profile
Barry Stuart Prystowsky
NPI 1801976048
$597.35
in general payments reported to CMS, 2019-2025
13 companies · $47.55 in 2025
The $47.55 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $74.31 · 2021: $71.03 · 2022: $176 · 2023: $80.73 · 2024: $37.89 · 2025: $47.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $103.13 | 2019-2022 | |
| Pfizer INC. | $83.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $76.99 | 2022-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $71.37 | 2020-2021 | |
| Cranial Technologies, INC | $68.71 | 2019-2022 | |
| Sanofi Pasteur INC. | $44.94 | 2023-2024 | |
| Kaleo, INC. | $39.13 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $32.74 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $22.42 | 2022 | |
| Seqirus USA INC | $15.00 | 2022 | |
| Sobi, INC | $13.74 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.26 | 2022 | |
| Phadia US INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Prystowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.